Brief: Lucira Says Its At Home Molecular Tests Can Detect Omicron Variant
Nov 29 (Reuters) - Lucira Health Inc LHDX.O :
* LUCIRA'S AT HOME MOLECULAR TESTS CAN DETECT OMICRON
(B.1.1.529)
SARS COV-2 VARIANT OF CONCERN
* LUCIRA - CONFIRMS COVID-19 CHECK-IT (OTC) AND ALL-IN-ONE
(RX)
MOLECULAR SELF-TEST KITS' ABILITY TO DETECT 100% OF OMICRON
VARIANT GENOME SEQUENCES ANALYZED
* LUCIRA HEALTH - LUCIRA ASSAYS TARGET VIRAL SEQUENCE
REGIONS
UNAFFECTED BY SPIKE PROTEIN MUTATIONS FOUND IN OMICRON, DELTA
AND OTHER VARIANTS OF CONCERN
Source text for Eikon: ID:nGNXG2dLt
Further company coverage: LHDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lucira Health
See all newsBrief: Lucira Health Inc Filed Its Amended Chapter 11 Plan Of Liquidation With Bankruptcy Court
Brief: Lucira Health Files Proposed Chapter 11 Plan Of Liquidation
Brief: Bankruptcy Court Approves Lucira Health Assets Sale To Pfizer
Brief: Lucira Health Inc Says On April 6, 2023 Co Held Auction Relating To Disposition Of All Or Substantially All Of Company's Assets
Brief: Lucira Health Announces U.S. Launch Of First & Only At-Home Combination Covid-19 & Flu Test Amidst Sale Process